Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers
- 17 June 2011
- journal article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 137 (8) , 1219-1228
Abstract
We have recently reported that peroxisome proliferator-activated receptor gamma (PPARγ) ligands produce antitumor effects against human ovarian cancer in conjunction with reduction in angiogenesis and induction of apoptosis via regulating prostaglandin (PG) E2 level. In this study, we investigated the effects of combination of ciglitazone, a PPARγ ligand, and cisplatin, a cytotoxic anti-cancer drug, on growth of ovarian cancer. Tumor growth and survival were examined in female nu/nu mice xenografted with subcutaneous OVCAR-3 tumors or with intraperitoneal DISS tumors and treated with cisplatin alone (5 mg/kg intraperitoneally once on day 1), ciglitazone alone (15 mg/kg intraperitoneally once a week), or the combination. Ciglitazone alone, cisplatin alone, or their combination significantly suppressed the growth of OVCAR-3 tumors xenotransplated subcutaneously and prolonged the survival of mice with malignant ascites derived from DISS cells as compared with the control. Furthermore, the combination produced a significantly greater antitumor effect than cisplatin or ciglitazone alone and also significantly prolonged the survival time as compared with cisplatin or ciglitazone alone. The combination significantly decreased PGE2 concentration in serum as well as in ascites, reduced vascular endothelial growth factor as well as microvessel density, and induced apoptosis in solid OVCAR-3 tumor as compared with cisplatin or ciglitazone alone. The combination remarkably decreased the expression of cyclooxygenase-2 (COX-2), microsomal PG E synthase (mPGES), and PG receptor 3 (EP3) in tumors. In vitro experiment showed that ciglitazone enhances the cytotoxicity of cisplatin against ovarian cancer cells. In conclusion, the combination inhibited the growth of ovarian cancer in conjunction with reduction in angiogenesis and induction of apoptosis resulting from suppression of PGE2 activation through decreasing the expression of COX-2, mPGES, and EP3. The inhibitory effect of this combination treatment on growth of ovarian cancer suggests a potential to lead a novel therapeutic strategy against ovarian cancer.Keywords
This publication has 36 references indexed in Scilit:
- Inhibitory effect of meloxicam, a selective cyclooxygenase‐2 inhibitor, and ciglitazone, a peroxisome proliferator‐activated receptor gamma ligand, on the growth of human ovarian cancersCancer, 2007
- Clofibric acid, a peroxisome proliferator–activated receptor α ligand, inhibits growth of human ovarian cancerMolecular Cancer Therapeutics, 2007
- Peroxisome Proliferator-Activated Receptor γ Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate CancerMolecular and Cellular Biology, 2006
- Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator–Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth InhibitionCancer Research, 2005
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- IL‐1β‐dependent activation of NF‐κB mediates PGE2 release via the expression of cyclooxygenase‐2 and microsomal prostaglandin E synthaseFEBS Letters, 2003
- Clinicopathologic Implications ofhMSH2Gene ExpressionCancer Biology & Therapy, 2002
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.Journal of Cell Biology, 1992
- Prostaglandin and Thromboxane Production in Ovarian Cancer TissueGynecologic and Obstetric Investigation, 1984
- Prostacyclin and thromboxane in ovarian cancer: Effect of cytostatics and prostaglandin synthesis inhibitorsGynecologic Oncology, 1983